Back

Coinbase CEO’s Longevity Startup NewLimit Secures $45 Million Funding

NewLimit raises $45 million from prominent venture firms and institutions to advance clinical trials targeting liver rejuvenation technology.

Summary

NewLimit, a longevity research company co-founded by Coinbase CEO, raised $45 million from Lilly Ventures, Duke University, S32, and Abstract. The investment round also saw participation from Kleiner Perkins, Dimension, Human Capital, and Boost VC. The funds will support clinical trials for a technology aimed at restoring youthful liver function.

Terms & Concepts
  • Longevity Research: A scientific field focused on understanding and extending human lifespan through medical and technological innovations.
  • Clinical Trials: Research studies conducted in phases to evaluate the safety and effectiveness of medical treatments or devices in humans.
  • Venture Capital: A form of private equity financing provided to startups and early-stage companies with high growth potential in exchange for equity.